Filtered By:
Condition: Menopause
Drug: Tamoxifen
This page shows you your search results in order of date.
Order by Relevance | Date
Total 115 results found since Jan 2013.
Managing Menopausal Symptoms: Common Questions and Answers
Am Fam Physician. 2023 Jul;108(1):28-39.ABSTRACTMenopausal symptoms are widespread and significantly impact quality of life. Common symptoms of menopause are vasomotor (i.e., hot flashes and night sweats) and genitourinary (e.g., vulvovaginal irritation and dryness, dyspareunia, urinary problems), although women may also experience changes in sexual function, mood, and sleep. Estrogen-containing hormone therapy is effective treatment for vasomotor symptoms. Nonhormonal medications for vasomotor symptoms include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and gabapentin. Selective ...
Source: American Family Physician - July 13, 2023 Category: Primary Care Authors: Jennifer G Chang Meghan N Lewis Maggie C Wertz Source Type: research
Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast Cancer
J Clin Oncol. 2023 May 1:JCO2300455. doi: 10.1200/JCO.23.00455. Online ahead of print.ABSTRACTThe Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.Patients with high...
Source: Clinical Genitourinary Cancer - May 1, 2023 Category: Cancer & Oncology Authors: Alison Laws Rinaa S Punglia Source Type: research
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
CONCLUSION: Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS. Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor-positive breast cancer.PMID:37079878 | DOI:10.1200/JCO.22.00577
Source: Clinical Breast Cancer - April 20, 2023 Category: Cancer & Oncology Authors: Takuji Iwase Shigehira Saji Kotaro Iijima Kenji Higaki Shoichiro Ohtani Yasuyuki Sato Yasuo Hozumi Yoshie Hasegawa Yasuhiro Yanagita Hiroyuki Takei Maki Tanaka Hideji Masuoka Masahiko Tanabe Chiyomi Egawa Yoshifumi Komoike Toshitaka Nakamura Hiroshi Ohtsu Source Type: research
Presidential reflections: how we got here, where we might go
Climacteric. 2023 Apr 3:1-9. doi: 10.1080/13697137.2023.2166823. Online ahead of print.ABSTRACTPieter van Keep was a founder and the third president of the International Menopause Society (IMS). He died, sadly, in 1991. Since then, every retiring president of the IMS has delivered the Pieter van Keep Memorial Lecture. This is an edited version of that lecture delivered at the 18th World Congress of the IMS in Lisbon, Portugal in 2022. In the article, President Steven R. Goldstein describes the path he followed that led him to the presidency of the IMS, including his original entry into transvaginal ultrasound, then gynecol...
Source: Climacteric - April 3, 2023 Category: Geriatrics Authors: S R Goldstein Source Type: research
